Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xilonix in metastatic colorectal cancer
NCT01767857Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2013
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of bermekimab in metastatic colorectal cancer (mCRC), sponsored by Janssen Pharmaceutical. Started Mar 2013; status: terminated.
02
Drugs
bermekimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01767857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767857.